GlassScriptPhysician profile
Pamela Kulback
NPI 1942282173
$6,597.90
in general payments reported to CMS, 2019-2025
29 companies · $600 in 2025
The $600 reported for 2025 was more than what 81% of Diagnostic Radiology providers received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,097 · 2020: $979 · 2021: $1,033 · 2022: $411 · 2023: $538 · 2024: $940 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,077.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,077.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,679.96 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Galderma Laboratories, L.P. | $769.55 | 2019-2025 | Dysport |
| Amgen INC. | $548.71 | 2019-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $455.16 | 2019 | |
| Lilly USA, LLC | $446.27 | 2019-2025 | Jardiance, Mounjaro |
| Amarin Pharma, INC. | $329.96 | 2019-2021 | |
| Merz North America, INC. | $315.56 | 2022-2025 | |
| Pfizer INC. | $259.59 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $220.44 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Janssen Pharmaceuticals, INC | $213.84 | 2020 | |
| Exact Sciences Corporation | $139.53 | 2023-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $121.65 | 2019-2023 | Eliquis |
| Dexcom, INC. | $119.57 | 2021-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $118.71 | 2019 | |
| Optinose US, INC. | $117.19 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $117.17 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.60 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $85.62 | 2021-2023 | Gvoke Hypopen, Keveyis |
| Allergan, INC. | $80.02 | 2019 | |
| Glaxosmithkline, LLC. | $75.82 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $60.19 | 2022-2023 | |
| Abbvie INC. | $60.12 | 2022-2023 | |
| Eisai INC. | $47.34 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $26.28 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.10 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.71 | 2025 | |
| Inspire Medical Systems, INC. | $17.69 | 2025 | Inspire |
| Abbott Laboratories | $17.39 | 2023 | Proclaim |
| Idorsia Pharmaceuticals US INC | $16.16 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Kulback listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.